HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brunner, E. J. Articles by Marmot, M. G. Search for Related Content PubMed PubMed Citation Articles by Brunner, E. J. Articles by Marmot, M. G. Social Bookmarking                What's this?

Relation Between Blood Glucose and Coronary Mortality Over 33 Years in the Whitehall Study

From the Department of Epidemiology and Public Health, University College London, London, U.K

Address correspondence and reprint requests to Eric J. Brunner, PhD, 1-19 Torrington Pl., London WC1E 6BT, England. E-mail: e.brunner{at}ucl.ac.uk

OBJECTIVE—Glucose intolerance is a risk factor for coronary disease, but there is uncertainty about the shape of the dose-response relationship between glucose level and risk of coronary mortality. We examined the prospective relation of 2-h postload blood glucose (2hBG) with coronary and other major causes of mortality over 33 years.

RESEARCH DESIGN AND METHODS—A 50-g oral glucose tolerance test (OGTT) was performed at baseline (1967–1969) in 17,869 male civil servants aged 40–64 years.

RESULTS—There were 3,561 coronary deaths during 451,787 person-years of observation. All-cause, cardiovascular, and respiratory mortality were elevated among participants with glucose intolerance. The hazard of coronary mortality rose from 2hBG = 4.6 mmol/l (83 mg/dl [95% CI 4.2–5.3]). The dose-response relation was best fitted by a single slope above this level, with no evidence of nonlinearity, compared with Cox models using other threshold levels, and those containing log 2hBG terms. There was no evidence for a dose-response relationship below 2hBG = 4.6 mmol/l. Between this level and 11.1 mmol/l (200 mg/dl), the age-adjusted hazard ratio was 3.62 (95% CI 2.3–5.6). The graded relationship was attenuated by 45% after adjustment for baseline coronary heart disease (CHD), BMI, systolic blood pressure, blood cholesterol, smoking, physical activity, lung function, and employment grade.

CONCLUSIONS—A threshold model with linear slope best described the dose-response relationship between postload blood glucose and CHD mortality risk.

Abbreviations: 2hBG, 2-h postload blood glucose • CHD, coronary heart disease • CVD, cardiovascular disease • OGTT, oral glucose tolerance test

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. C. Gerstein, K. Swedberg, J. Carlsson, J. J. V. McMurray, E. L. Michelson, B. Olofsson, M. A. Pfeffer, S. Yusuf, and for the CHARM Program Investigators The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure: An Analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program Arch Intern Med, August 11, 2008; 168(15): 1699 - 1704. [Abstract] [Full Text] [PDF]

				T. T. Nguyen, J. J. Wang, and T. Y. Wong Retinal Vascular Changes in Pre-Diabetes and Prehypertension: New findings and their research and clinical implications Diabetes Care, October 1, 2007; 30(10): 2708 - 2715. [Full Text] [PDF]

				K. Bulhoes and L. Araujo Metabolic Syndrome in Hypertensive Patients: Correlation between anthropometric data and laboratory findings Diabetes Care, June 1, 2007; 30(6): 1624 - 1626. [Full Text] [PDF]

				B. P. Childs, N. C. Kesty, E. Klein, R. Rubin, and A. Wick Considering Pramlintide Therapy for Postprandial Blood Glucose Control Diabetes Spectr, April 1, 2007; 20(2): 108 - 114. [Abstract] [Full Text] [PDF]

				N. M. Selby, J. Fialova, J. O. Burton, and C. W. McIntyre The haemodynamic and metabolic effects of hypertonic-glucose and amino-acid-based peritoneal dialysis fluids Nephrol. Dial. Transplant., March 1, 2007; 22(3): 870 - 879. [Abstract] [Full Text] [PDF]

				J. S. Pankow, D. K. Kwan, B. B. Duncan, M. I. Schmidt, D. J. Couper, S. Golden, and C. M. Ballantyne Cardiometabolic Risk in Impaired Fasting Glucose and Impaired Glucose Tolerance: The Atherosclerosis Risk in Communities Study Diabetes Care, February 1, 2007; 30(2): 325 - 331. [Abstract] [Full Text] [PDF]

				R. H. Eckel, R. Kahn, R. M. Robertson, and R. A. Rizza Preventing Cardiovascular Disease and Diabetes: A call to action from the American Diabetes Association and the American Heart Association Diabetes Care, July 1, 2006; 29(7): 1697 - 1699. [Full Text] [PDF]

				R. H. Eckel, R. Kahn, R. M. Robertson, and R. A. Rizza Preventing Cardiovascular Disease and Diabetes: A Call to Action From the American Diabetes Association and the American Heart Association Circulation, June 27, 2006; 113(25): 2943 - 2946. [Full Text] [PDF]

				L. S. Phillips, W. S. Weintraub, D. C. Ziemer, P. Kolm, J. K. Foster, V. Vaccarino, M. K. Rhee, R. K. Budhwani, and J. M. Caudle All Pre-Diabetes Is Not the Same: Metabolic and Vascular Risks of Impaired Fasting Glucose at 100 Versus 110 mg/dl: The Screening for Impaired Glucose Tolerance Study 1 (SIGT 1). Diabetes Care, June 1, 2006; 29(6): 1405 - 1407. [Full Text] [PDF]